Research: Update Existing Regulatory Concepts

Summary

This research document synthesizes current enforcement standards for functional beverages and dietary supplements in the United States, governed jointly by the fda and the ftc. It highlights a dual trend: aggressive FTC pursuit of civil penalties and high-quality randomized-controlled-trials (RCTs) for unsupported health claims, alongside FDA crackdowns on unapproved ingredients in conventional foods. The tightening regulatory landscape creates significant hurdles for brands attempting to balance clinical efficacy with beverage economics and taste.

FTC Enforcement & Substantiation Standards

• Enforcement Shift to Civil Penalties: Following a ruling by the supreme-court-of-the-united-states (AMG Capital Management v. FTC) that limited the agency’s ability to seek equitable monetary relief, the ftc has pivoted to issuing notices-of-penalty-offenses. In April 2023, nearly 700 companies received these notices, establishing “actual knowledge” of deceptive conduct and allowing the FTC to seek civil penalties of up to $50,120 per violation for unsubstantiated claims.
• The CRSE Standard and RCTs: The FTC is heavily scrutinizing functional beverage brands, shifting from a “flexible” approach to a strict expectation of competent-and-reliable-scientific-evidence (CRSE) and RCTs to close the clinical-substantiation-gap. Failure to meet this standard results in severe penalties, such as the $5.5 million settlement with dietary supplement maker iovate over unsubstantiated weight-loss claims.
• Borrowed Science & Essential Equivalence: To avoid funding proprietary clinical trials, brands often rely on existing scientific literature. However, the FTC mandates strict borrowed-science-essential-equivalence. Brands cannot cite general studies about an ingredient; their specific beverage formulation must be “essentially equivalent” in dosage, form, and route of administration to the product used in the cited study.
• Statistical vs. Clinical Meaningfulness: The FTC draws a firm line regarding statistical-significance-vs-clinical-meaningfulness, ensuring brands cannot use massive sample sizes to prove trivial or practically unnoticeable health benefits.
• Escalation for Specific Claims: The FTC will escalate the burden of proof for specific disease-prevention claims. Precedents include the 2010 FTC consent decree with nestle, which established a stricter “two-RCT” minimum for certain claims, and the case of brain-research-labs-llc, which illustrates the legal paradoxes surrounding the flexibility of the CRSE standard.

FDA Enforcement & Labeling

• Crackdown on Botanicals: The fda is actively issuing Warning Letters to functional beverage makers utilizing unapproved ingredients. Botanicals and adaptogens like ginkgo, eleuthero, and echinacea must be gras-generally-recognized-as-safe to be used in conventional foods; otherwise, the products are deemed adulterated. This highlights the ongoing beverage-vs-supplement-ambiguity.
• DSHEA Disclaimer Enforcement Discretion: In a rare concession to reduce label clutter, the FDA announced it will exercise “enforcement discretion” in 2025–2026 regarding the placement of the mandatory DSHEA disclaimer for structure-function-vs-drug-claims. Brands no longer need to print the disclaimer on every single panel where a claim is made, provided it is present on the label and properly linked.

Strategic Implications

For beverage conglomerates like Asahi exploring the functional adult soft drink space in the US, navigating these dual regulatory hurdles is critical:

1. The Beverage vs. Supplement Paradox: The GRAS requirement means an adaptogen that is perfectly legal in a dietary supplement capsule may be illegal when formulated into a liquid conventional beverage.
2. The Dosage vs. Economics Tension: Adhering to the FTC’s “essential equivalence” rule creates a severe tension between clinical dosage realities and beverage economics. Matching the clinical dosages of adaptogens required to make legal claims often ruins standard Cost of Goods Sold (COGS) or proves organoleptically disastrous (ruining the taste profile of the beverage).
3. Legal Guesswork: The vague mathematical thresholds for what constitutes “competent and reliable scientific evidence” leave brands in a state of legal vulnerability, exposed to aggressive FTC penalties if their substantiation is deemed insufficient.